301258 富士莱
已收盘 07-15 15:00:00
资讯
新帖
简况
富士莱:截至2025年7月10日股东总户数为14,849户
证券之星 · 07-14 07:37
富士莱:截至2025年7月10日股东总户数为14,849户
7月10日富士莱跌5.95%,银河康乐股票A基金重仓该股
证券之星 · 07-10
7月10日富士莱跌5.95%,银河康乐股票A基金重仓该股
富士莱:硫辛酸系列产品中颗粒硫辛酸是R-硫辛酸和S-硫辛酸的混合物
证券之星 · 07-09
富士莱:硫辛酸系列产品中颗粒硫辛酸是R-硫辛酸和S-硫辛酸的混合物
7月8日富士莱(301258)龙虎榜数据:游资章盟主上榜
证券之星 · 07-08
7月8日富士莱(301258)龙虎榜数据:游资章盟主上榜
异动快报:富士莱(301258)7月8日9点33分触及涨停板
证券之星 · 07-08
异动快报:富士莱(301258)7月8日9点33分触及涨停板
【富士莱:拟2,000万元-4,000万元回购股份】富士莱公告,公司拟2,000万元-4,000万元回购股份,资金来源为自有资金,回购价格不超过40元/股,回购股份将在未来用于实施股权激励计划或员工持股计划。
金融界 · 07-07
【富士莱:拟2,000万元-4,000万元回购股份】富士莱公告,公司拟2,000万元-4,000万元回购股份,资金来源为自有资金,回购价格不超过40元/股,回购股份将在未来用于实施股权激励计划或员工持股计划。
富士莱:截至2025年6月30日股东总户数为12,186户
证券之星 · 07-01
富士莱:截至2025年6月30日股东总户数为12,186户
富士莱:控股股东及实控人低于发行价不得减持股份
证券之星 · 06-26
富士莱:控股股东及实控人低于发行价不得减持股份
富士莱(301258)6月20日股东户数1.2万户,较上期减少6.67%
证券之星 · 06-24
富士莱(301258)6月20日股东户数1.2万户,较上期减少6.67%
富士莱:截至2025年6月20日股东总户数为11,996户
证券之星 · 06-23
富士莱:截至2025年6月20日股东总户数为11,996户
每周股票复盘:富士莱(301258)股东户数减少203户,户均持股增至7132股
证券之星 · 06-14
每周股票复盘:富士莱(301258)股东户数减少203户,户均持股增至7132股
富士莱:截至2025年6月10日股东总户数为12,853户
证券之星 · 06-11
富士莱:截至2025年6月10日股东总户数为12,853户
每周股票复盘:富士莱(301258)股东户数减少1492户,户均持股增至7021股
证券之星 · 06-07
每周股票复盘:富士莱(301258)股东户数减少1492户,户均持股增至7021股
富士莱:苏州贝格致远投资管理有限公司的业务范围主要是股权投资、创业投资等
证券之星 · 06-06
富士莱:苏州贝格致远投资管理有限公司的业务范围主要是股权投资、创业投资等
富士莱:公司生物酶催化法生产的R-硫辛酸已经实现量产
证券之星 · 06-04
富士莱:公司生物酶催化法生产的R-硫辛酸已经实现量产
富士莱:公司与恒瑞医药合作的原料药项目有艾瑞昔布、甲磺酸阿帕替尼
证券之星 · 06-04
富士莱:公司与恒瑞医药合作的原料药项目有艾瑞昔布、甲磺酸阿帕替尼
富士莱:截至2025年5月30日股东总户数为13,056户
证券之星 · 06-04
富士莱:截至2025年5月30日股东总户数为13,056户
5月30日富士莱跌9.04%,银河康乐股票A基金重仓该股
证券之星 · 05-30
5月30日富士莱跌9.04%,银河康乐股票A基金重仓该股
富士莱:硫辛酸在医药领域用于糖尿病周围神经病变等多种疾病的治疗
证券之星 · 05-30
富士莱:硫辛酸在医药领域用于糖尿病周围神经病变等多种疾病的治疗
富士莱:公司将持续聚焦主业,强化核心竞争力,努力提升长期投资价值
证券之星 · 05-30
富士莱:公司将持续聚焦主业,强化核心竞争力,努力提升长期投资价值
加载更多
公司概况
公司名称:
苏州富士莱医药股份有限公司
所属行业:
医药制造业
上市日期:
2022-03-29
主营业务:
苏州富士莱医药股份有限公司的主营业务是医药中间体、原料药以及保健品原料的研发、生产与销售。公司的主要产品是颗粒硫辛酸、R-硫辛酸、R-硫辛酸氨基丁三醇盐、6,8-二氯辛酸乙酯、甘油磷脂酰胆碱(GPC)、L-肌肽、艾瑞昔布原料药。
发行价格:
48.30
{"stockData":{"symbol":"301258","market":"SZ","secType":"STK","nameCN":"富士莱","latestPrice":33.34,"timestamp":1752563019000,"preClose":33.95,"halted":0,"volume":4148748,"delay":0,"changeRate":-0.018,"floatShares":33872000,"shares":91670000,"eps":0.377,"marketStatus":"已收盘","change":-0.61,"latestTime":"07-15 15:00:00","open":33.95,"high":33.95,"low":32.77,"amount":138000000,"amplitude":0.0348,"askPrice":33.35,"askSize":34,"bidPrice":33.34,"bidSize":76,"shortable":0,"etf":0,"ttmEps":0.377,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752629400000},"marketStatusCode":5,"adr":0,"adjPreClose":33.95,"symbolType":"stock","openAndCloseTimeList":[[1752543000000,1752550200000],[1752555600000,1752562800000]],"highLimit":37.35,"lowLimit":30.56,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":91670000,"isCdr":false,"pbRate":1.63,"roa":"--","peRate":88.435013,"roe":"1.26%","epsLYR":0.18,"committee":0.544262,"marketValue":3056000000,"turnoverRate":0.1225,"status":1,"floatMarketCap":1129000000},"requestUrl":"/m/hq/s/301258","defaultTab":"news","newsList":[{"id":"2551970724","title":"富士莱:截至2025年7月10日股东总户数为14,849户","url":"https://stock-news.laohu8.com/highlight/detail?id=2551970724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551970724?lang=zh_cn&edition=full","pubTime":"2025-07-14 15:37","pubTimestamp":1752478654,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,你好!请问截止至2025年7月10日,公司股东人数总数是多少?谢谢!富士莱回复:尊敬的投资者,您好!截至2025年7月10日股东总户数为14,849户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400016085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2550611717","title":"7月10日富士莱跌5.95%,银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550611717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550611717?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:18","pubTimestamp":1752135499,"startTime":"0","endTime":"0","summary":"证券之星消息,7月10日富士莱跌5.95%,收盘报34.0元,换手率25.39%,成交量8.6万手,成交额2.98亿元。7月10日的资金流向数据方面,主力资金净流出755.0万元,占总成交额2.54%,游资资金净流出297.55万元,占总成交额1.0%,散户资金净流入1052.55万元,占总成交额3.53%。重仓富士莱的公募基金请见下表:根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为银河基金的银河康乐股票A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000025145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2550686966","title":"富士莱:硫辛酸系列产品中颗粒硫辛酸是R-硫辛酸和S-硫辛酸的混合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2550686966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550686966?lang=zh_cn&edition=full","pubTime":"2025-07-09 15:45","pubTimestamp":1752047111,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,R-.硫辛酸是治疗糖尿病的重要药物之一,请问贵公司R-硫辛酸产能是多少,市场占有率是多少?谢谢!富士莱回复:尊敬的投资者,您好!硫辛酸系列产品中,颗粒硫辛酸(混旋)是R-硫辛酸(右旋)和S-硫辛酸(左旋)的混合物;R-硫辛酸由于生物活性更好,抗氧化功能强于颗粒硫辛酸。有关公司的经营数据,请以公司在指定信息披露媒体发布的公告为准。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900021752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2549517443","title":"7月8日富士莱(301258)龙虎榜数据:游资章盟主上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2549517443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549517443?lang=zh_cn&edition=full","pubTime":"2025-07-08 17:14","pubTimestamp":1751966073,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年7月8日公布的交易公开信息显示,富士莱因日换手率达到30%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月8日收盘,富士莱报收于36.1元,上涨10.3%,换手率46.85%,成交量15.87万手,成交额5.97亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出779.56万元。章盟主等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800028011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2549956277","title":"异动快报:富士莱(301258)7月8日9点33分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2549956277","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549956277?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:36","pubTimestamp":1751938596,"startTime":"0","endTime":"0","summary":"证券之星7月8日盘中消息,9点33分富士莱触及涨停板。目前价格39.28,上涨20.01%。其所属行业化学制药目前下跌。领涨股为福元医药。该股为化学原料药,化妆品,医药概念热股,当日化学原料药概念上涨1.55%,化妆品概念上涨1.49%,医药概念上涨1.32%。7月7日的资金流向数据方面,主力资金净流入589.06万元,占总成交额4.01%,游资资金净流入295.57万元,占总成交额2.01%,散户资金净流出884.63万元,占总成交额6.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800008608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2549935536","title":"【富士莱:拟2,000万元-4,000万元回购股份】富士莱公告,公司拟2,000万元-4,000万元回购股份,资金来源为自有资金,回购价格不超过40元/股,回购股份将在未来用于实施股权激励计划或员工持股计划。","url":"https://stock-news.laohu8.com/highlight/detail?id=2549935536","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549935536?lang=zh_cn&edition=full","pubTime":"2025-07-07 18:45","pubTimestamp":1751885101,"startTime":"0","endTime":"0","summary":"富士莱公告,公司拟2,000万元-4,000万元回购股份,资金来源为自有资金,回购价格不超过40元/股,回购股份将在未来用于实施股权激励计划或员工持股计划。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/07184551534939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2548080075","title":"富士莱:截至2025年6月30日股东总户数为12,186户","url":"https://stock-news.laohu8.com/highlight/detail?id=2548080075","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548080075?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:06","pubTimestamp":1751357182,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2025年六月 30日公司的股东总数是多少?谢谢富士莱回复:尊敬的投资者,您好!截至2025年6月30日股东总户数为12,186户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100025042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2546473302","title":"富士莱:控股股东及实控人低于发行价不得减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2546473302","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546473302?lang=zh_cn&edition=full","pubTime":"2025-06-26 20:52","pubTimestamp":1750942369,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:公司发行价超过48,目前股价只剩下29左右,跌幅高达40%以上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062600036040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2545407355","title":"富士莱(301258)6月20日股东户数1.2万户,较上期减少6.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545407355","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545407355?lang=zh_cn&edition=full","pubTime":"2025-06-24 17:23","pubTimestamp":1750757034,"startTime":"0","endTime":"0","summary":"证券之星消息,近日富士莱披露,截至2025年6月20日公司股东户数为1.2万户,较6月10日减少857.0户,减幅为6.67%。在化学制药行业个股中,富士莱股东户数低于行业平均水平,截至6月20日,化学制药行业平均股东户数为3.25万户。从股价来看,2025年6月10日至2025年6月20日,富士莱区间跌幅为10.98%,在此期间股东户数减少857.0户,减幅为6.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400028306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2545955374","title":"富士莱:截至2025年6月20日股东总户数为11,996户","url":"https://stock-news.laohu8.com/highlight/detail?id=2545955374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545955374?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:18","pubTimestamp":1750666704,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问:请问最新一期公司的股东人数是多少?富士莱回复:尊敬的投资者,您好!截至2025年6月20日股东总户数为11,996户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062300018371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2543652679","title":"每周股票复盘:富士莱(301258)股东户数减少203户,户均持股增至7132股","url":"https://stock-news.laohu8.com/highlight/detail?id=2543652679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543652679?lang=zh_cn&edition=full","pubTime":"2025-06-14 11:17","pubTimestamp":1749871027,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘,富士莱报收于30.26元,较上周的30.52元下跌0.85%。本周,富士莱6月10日盘中最高价报33.11元。富士莱当前最新总市值27.74亿元,在化学制药板块市值排名134/150,在两市A股市值排名4369/5150。本周关注点股本股东变化:截至2025年6月10日公司股东户数为1.29万户,较5月30日减少203.0户股本股东变化:户均持股数量由上期的7021.0股增加至7132.0股股本股东变化近日富士莱披露,截至2025年6月10日公司股东户数为1.29万户,较5月30日减少203.0户,减幅为1.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400011474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2542667303","title":"富士莱:截至2025年6月10日股东总户数为12,853户","url":"https://stock-news.laohu8.com/highlight/detail?id=2542667303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542667303?lang=zh_cn&edition=full","pubTime":"2025-06-11 15:51","pubTimestamp":1749628285,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问题最新一期的公司股东人数是多少?富士莱回复:尊敬的投资者,您好!截至2025年6月10日股东总户数为12,853户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100020087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2541922658","title":"每周股票复盘:富士莱(301258)股东户数减少1492户,户均持股增至7021股","url":"https://stock-news.laohu8.com/highlight/detail?id=2541922658","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541922658?lang=zh_cn&edition=full","pubTime":"2025-06-07 10:05","pubTimestamp":1749261914,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘,富士莱报收于30.52元,较上周的30.38元上涨0.46%。本周,富士莱6月3日盘中最高价报32.8元。本周关注点股本股东变化:截至2025年5月30日公司股东户数为1.31万户,较5月20日减少1492.0户股本股东变化近日富士莱披露,截至2025年5月30日公司股东户数为1.31万户,较5月20日减少1492.0户,减幅为10.26%。户均持股数量由上期的6301.0股增加至7021.0股,户均持股市值为21.33万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700009882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2541500839","title":"富士莱:苏州贝格致远投资管理有限公司的业务范围主要是股权投资、创业投资等","url":"https://stock-news.laohu8.com/highlight/detail?id=2541500839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541500839?lang=zh_cn&edition=full","pubTime":"2025-06-06 16:06","pubTimestamp":1749197188,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)06月06日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,董秘,子公司苏州贝格致远投资管理有限公司主要投资哪类企业?富士莱回复:尊敬的投资者,您好!苏州贝格致远投资管理有限公司的业务范围主要是股权投资、创业投资等。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060600022132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2540037967","title":"富士莱:公司生物酶催化法生产的R-硫辛酸已经实现量产","url":"https://stock-news.laohu8.com/highlight/detail?id=2540037967","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540037967?lang=zh_cn&edition=full","pubTime":"2025-06-04 16:06","pubTimestamp":1749024368,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,董秘,贵公司合成生物产品及技术有哪些?富士莱回复:尊敬的投资者,您好!公司生物酶催化法生产的R-硫辛酸已经实现量产,主要用于对外销售及制备R-硫辛酸钠盐,目前尚处于市场推广阶段,能否完全取代原有工艺取决于市场需求、客户接受程度等多方面因素。公司始终密切关注合成生物学技术的发展,感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400021890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2540375460","title":"富士莱:公司与恒瑞医药合作的原料药项目有艾瑞昔布、甲磺酸阿帕替尼","url":"https://stock-news.laohu8.com/highlight/detail?id=2540375460","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540375460?lang=zh_cn&edition=full","pubTime":"2025-06-04 16:01","pubTimestamp":1749024075,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,董秘,恒瑞医药与公司长期合作,请问有创新药物方面的合作吗?富士莱回复:尊敬的投资者,您好!公司与恒瑞医药合作的原料药项目有艾瑞昔布、甲磺酸阿帕替尼。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400021373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU2148510915.USD","LU1064130708.USD","BK0196","BK0183","BK0028","01276","BK0012","LU1328615791.USD","BK0239","LU2328871848.SGD","LU0405327494.USD","LU1064131003.USD","LU2488822045.USD","BK0188","600276","LU0405327148.USD","BK1191","BK0060","301258"],"gpt_icon":0},{"id":"2540208069","title":"富士莱:截至2025年5月30日股东总户数为13,056户","url":"https://stock-news.laohu8.com/highlight/detail?id=2540208069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540208069?lang=zh_cn&edition=full","pubTime":"2025-06-04 11:33","pubTimestamp":1749008020,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2025年五月 30日公司的股东总数是多少?谢谢富士莱回复:尊敬的投资者,您好!截至2025年5月30日股东总户数为13,056户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400012868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2539724184","title":"5月30日富士莱跌9.04%,银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2539724184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539724184?lang=zh_cn&edition=full","pubTime":"2025-05-30 16:34","pubTimestamp":1748594084,"startTime":"0","endTime":"0","summary":"证券之星消息,5月30日富士莱跌9.04%,收盘报30.38元,换手率21.87%,成交量7.41万手,成交额2.33亿元。融资融券方面近5日融资净流入509.45万,融资余额增加;融券净流入0.0,融券余额增加。重仓富士莱的公募基金请见下表:根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为银河基金的银河康乐股票A。银河康乐股票A目前规模为1.43亿元,最新净值2.439,较上一交易日上涨2.82%,近一年上涨17.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053000026103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2539246073","title":"富士莱:硫辛酸在医药领域用于糖尿病周围神经病变等多种疾病的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2539246073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539246073?lang=zh_cn&edition=full","pubTime":"2025-05-30 16:12","pubTimestamp":1748592738,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)05月30日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,董秘,贵公司硫辛酸产品对神经损伤和大脑发育有保护作用吗?富士莱回复:尊敬的投资者,您好!硫辛酸在医药领域,用于糖尿病周围神经病变、神经系统并发症等多种疾病的治疗;在保健品领域,具有清除体内自由基、防止脂质过氧化效果,可以延缓衰老、美颜以及活化细胞,用于口服营养品。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053000024000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","159938","09939","BK1574","BK0239","301258"],"gpt_icon":0},{"id":"2539467762","title":"富士莱:公司将持续聚焦主业,强化核心竞争力,努力提升长期投资价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2539467762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539467762?lang=zh_cn&edition=full","pubTime":"2025-05-30 16:12","pubTimestamp":1748592733,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)05月30日在投资者关系平台上答复投资者关心的问题。投资者提问:懂秘您好:R-硫锌酸,涨价了没?若涨价了,对公司营业收入带来影响如何?贵公司有市值管理计划吗?上市3年,依旧破发状态,贵公司如何保障投资者利益呢?最后希望贵公司做大做强!富士莱回复:尊敬的投资者,您好!公司将持续聚焦主业,强化核心竞争力,努力提升长期投资价值。具体经营数据敬请关注后续公司对外披露的定期报告等相关公告。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053000023994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752610193975,"stockEarnings":[{"period":"1week","weight":-0.0765},{"period":"1month","weight":0.1018},{"period":"3month","weight":0.4132},{"period":"6month","weight":0.4544},{"period":"1year","weight":0.3914},{"period":"ytd","weight":0.4156}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.0379},{"period":"3month","weight":0.0699},{"period":"6month","weight":0.0831},{"period":"1year","weight":0.1785},{"period":"ytd","weight":0.0457}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州富士莱医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14849人(较上一季度增加21.85%)","perCapita":"2281股","listingDate":"2022-03-29","address":"江苏省苏州市常熟市新材料产业园海旺路16号","registeredCapital":"9167万元","survey":" 苏州富士莱医药股份有限公司的主营业务是医药中间体、原料药以及保健品原料的研发、生产与销售。公司的主要产品是颗粒硫辛酸、R-硫辛酸、R-硫辛酸氨基丁三醇盐、6,8-二氯辛酸乙酯、甘油磷脂酰胆碱(GPC)、L-肌肽、艾瑞昔布原料药。","listedPrice":48.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供富士莱(301258)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"富士莱,301258,富士莱股票,富士莱股票老虎,富士莱股票老虎国际,富士莱行情,富士莱股票行情,富士莱股价,富士莱股市,富士莱股票价格,富士莱股票交易,富士莱股票购买,富士莱股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供富士莱(301258)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}